When does Ongentys (opicapone) lose exclusivity?
Ongentys is the brand name for opicapone. The provided information doesn’t include the specific regulatory exclusivity end date(s) for Ongentys in any country (such as the EU “data exclusivity/market exclusivity” clocks, or US patent term/exclusivity expirations). To determine the exact “loss of exclusivity” date, you need either:
- the market/country you mean (US vs EU/UK vs other), and
- the relevant reference(s) (patent list or regulator exclusivity database), because “exclusivity” can refer to different protections.
What kind of exclusivity could apply to Ongentys?
“Loss of exclusivity” can mean different legal protections, commonly including:
- Patent expiry (including any patent term adjustments or extensions).
- Regulatory data exclusivity (protection for clinical/data packages).
- Marketing exclusivity (protection against generic/biosimilar approval or certain competing applications, depending on jurisdiction).
Because the exact mix depends on jurisdiction and the specific product authorization history, the end date can differ even when the active ingredient is the same.
How can you find the exact exclusivity end date for your country?
Search using one of these approaches:
- For the EU/UK: look up “market authorization” and exclusivity periods tied to the original marketing authorization and member state rules.
- For the US: check the FDA’s Orange Book for listed patents for Ongentys and any related regulatory exclusivity, then identify the relevant expiration dates and any listed “exclusivity” codes.
- For other markets: use the local medicines regulator’s patent/exclusivity register or payer/HTA dossiers that often summarize expiry timelines.
Does Ongentys face generic or competitor entry as exclusivity ends?
Whether generic entry is possible right at expiry depends on what exactly expires first:
- If patents expire but data/marketing exclusivity remain, regulators may still block certain approvals.
- If only some patents expire, “evergreening” via additional patents can delay competition.
- If patents are still active (including patent litigation outcomes), the first generic/biosimilar launch can be later than the earliest stated expiry.
To answer this precisely for Ongentys, you’d need the relevant patent/exclusivity listings and any known litigation or regulatory status.
What you should tell me to get a precise date
If you share:
1) the country/region (e.g., US, EU, UK), and
2) whether you want “first generic launch date” or “earliest legal protection expiry date,”
I can narrow it to the correct exclusivity type and explain how the timeline maps to market entry.
Sources
No sources were provided in the prompt to cite specific Ongentys exclusivity timelines.